News | Heart Valve Technology | June 09, 2015

Medtronic CoreValve Evolut R System Yields Positive Outcomes in First Clinical Study

Recapturable valve shows no mortality or stroke at 30 days

Medtronic, CoreValve Evolut R, first clinical study, ACC.15

June 9, 2015 - Medtronic plc announced initial clinical outcomes for its next-generation CoreValve Evolut R System at the 64th annual scientific session of the American College of Cardiology, March 14-16 in San Diego. At 30-days, the recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. The Evolut R Study enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand.

The system is not approved for commercial use in the United States, where it is currently undergoing clinical trials.

"Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR [transcatheter aortic valve replacement] technology that provides increased confidence with recapturability, excellent procedural results and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia,  who is a co-principal investigator of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."

The EnVeo R Delivery Catheter System provides a new InLine Sheath that significantly reduces the profile to a 14 Fr equivalent, less than 1/5 inch. Transfemoral access was possible in all but one patient (98.3 percent) in a population that included patients with vasculature as small as 5mm diameter. All recapture attempts were performed safely with zero strokes (0.0 percent). Additionally, correct valve position with one device was achieved in 98.3 percent of patients, and there were no cases of valve dysfunction, procedural death, annular rupture, coronary occlusion, valve embolization or conversion to surgery in the study. The pacemaker rate was low at 11.7 percent.

The supra-annular valve design of the CoreValve Evolut R System resulted in low, single-digit mean aortic gradients (a commonly used threshold of exceptional blood flow) at each follow-up visit (9.2mm Hg in early follow-up at 24hrs to 7 days post-procedure, and 8.1mmHg at 30 days). The valve features a new extended sealing skirt on the 26 and 29 mm sizes that further promotes valve sealing at the annulus, resulting in low rates of paravalvular leak (PVL) with 96.6 percent of patients having ≤ mild PVL at 30-days.

The 23 mm, 26 mm and 29 mm sizes of the CoreValve Evolut R transcatheter valve and the CoreValve EnVeo R Delivery Catheter System are available in Europe and other countries that recognize the CE mark.

For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init